Leidos Biomedical Research INC
- UEI
- HV8BH9BPG8Y9
- SAM.gov registration
- Not checked yet
- Parent company
- Leidos Holdings, INC.
- Physical address
- 1050 BOYLES ST, FREDERICK, MD 21702
Forensic summary
LEIDOS BIOMEDICAL RESEARCH INC is a company located in Frederick, MD, and is a subsidiary of LEIDOS HOLDINGS, INC. In our records, the company has 24 contracts with a total obligated amount of $129.5 million. All of these contracts are with the Department of Health and Human Services, which accounts for 100% of the company's federal contracting activity. The company's primary industry is research and development in the physical, engineering, and life sciences, excluding nanotechnology and biotechnology. There are no exclusions listed for this vendor in our database.
The vendor has a risk score of 5 out of 100, indicating a low risk level. The only risk indicator identified is that the company's revenue is concentrated in a single agency, the Department of Health and Human Services. This concentration may suggest a dependency on one source of funding, which could be a factor to consider in procurement decisions. No other risk indicators were found in our database.
Written by AI only from the data on this page. Check the linked sources before relying on it.
Risk indicators
- Revenue concentrated in a single agency · share: 100%, agency: Department of Health and Human Services+5
The score adds up statistical indicators from public records. It is a prompt for review, not evidence of wrongdoing.
Stock market and financials (SEC)
Part of the Leidos Holdings, INC. group, which is publicly traded · LDOS · SEC EDGAR
| Fiscal year | Revenue | Net income | Operating cash flow | Assets | Equity | Long-term debt |
|---|---|---|---|---|---|---|
| 2025 | $17.2B | $1.4B | $1.8B | — | — | — |
| 2024 | $16.7B | $1.3B | $1.4B | $13B | $4.4B | — |
| 2023 | $15.4B | $199M | $1.2B | $12.7B | $4.2B | — |
| 2022 | $14.4B | $685M | $992M | $13.1B | $4.3B | — |
| 2021 | $13.7B | $753M | $1B | $13.3B | $4.3B | — |
Material events (8-K), last 3 years
- Oct 5, 2026 8-K · Material agreement, Regulation FD disclosure
- Oct 1, 2026 8-K · Director or officer change
- Aug 4, 2026 8-K · Results of operations
- May 6, 2026 8-K · Director or officer change, Shareholder vote
- May 5, 2026 8-K · Results of operations
- Apr 15, 2026 8-K · Material agreement, Regulation FD disclosure
- Mar 30, 2026 8-K · Acquisition or disposition of assets, Regulation FD disclosure
- Mar 3, 2026 8-K · Material agreement, New financial obligation
- Feb 17, 2026 8-K · Material agreement, New financial obligation
- Feb 17, 2026 8-K · Results of operations, Regulation FD disclosure
- Jan 26, 2026 8-K · Material agreement, Regulation FD disclosure
- Nov 4, 2025 8-K · Results of operations
Annual figures from official SEC filings (XBRL). Dependence compares federal contracts signed by group companies in the last 12 months (total contract value, which may span several years) with the latest annual revenue: a reference, not an accounting figure. Stock prices are not included.
Digital presence and cybersecurity
leidos.com · group website (Wikidata)
- ✓ Valid HTTPS
- ✓ HSTS enabled
- ✓ Content Security Policy
- ✓ Clickjacking protection
- ✓ SPF strict (-all)
- ✓ DMARC reject
Detected technology: DrupalGoogle Analytics / Tag ManagerjQueryDrupal 11
Passive check on Oct 29, 2026: only what any browser sees when opening the homepage and what the domain publishes in DNS (no scans or probing). It is a baseline best-practice reference, not a security audit; a missing header does not imply a vulnerability.
Telecommunications (FCC)
Services: Private land mobile · 2
Licenses from the FCC Universal Licensing System (ULS) weekly full files; FCC ID grantees from the FCC's official registry. Linked by exact licensee legal name; every FCC ID starts with the grantee code.
Linked entities
Links come from shared physical addresses, reported executives and parent companies. A link is not an accusation.
Contract history
| Award | Agency | Description | Signed | Obligated | Mods | Obligated / ceiling | Competition |
|---|---|---|---|---|---|---|---|
| 75N91026F00034 | National Institutes Of Health | FUNCTIONAL PRECISION MEDICINE AND RESPONSE ASSAYS | Sep 29, 2026 | $72,167,416 | 0 | ×1.00 | Competed |
| 75N91026F00033 | National Institutes Of Health | PALM004: AN OBSERVATIONAL STUDY OF THE NATURAL HISTORY OF BUNDIBUGYO VIRUS DISEASE | Sep 25, 2026 | $11,725,031 | 0 | ×1.00 | Competed |
| 75N91026F00032 | National Institutes Of Health | CLINICAL MATERIAL TECHNOLOGY DEVELOPMENT AND PILOT MANUFACTURING | Sep 24, 2026 | $17,712,309 | 0 | ×1.00 | Competed |
| 75N91026F00020 | National Institutes Of Health | NCI-ARCDCTD-26-0055 - CPTAC BIOSPECIMEN ACQUISITION, PROCESSING, AND DISTRIBUTION | — | $4,538,288 | 0 | — | — |
| 75N91026F00028 | National Institutes Of Health | 126797 CAMPUS REPLACE BSCS | — | $1,912,753 | 0 | — | — |
| 75N91026F00006 | National Institutes Of Health | FY26 126816_B539 _B536 W END FIRE ALARM | — | $1,756,369 | 0 | — | — |
| 75N91026F00009 | National Institutes Of Health | FY26 126771 - B1022 AUTOCLAVE REPLACEMENT | — | $1,747,456 | 0 | — | — |
| 75N91026F00026 | National Institutes Of Health | INTEGRATED DMPK AND TOXICOLOGY PROFILING OF NCATS/TDB MEDICINAL CHEMISTRY LEAD CANDIDATES | — | $1,683,296 | 0 | — | — |
| 75N91026F00023 | National Institutes Of Health | FFRDC DRUG PRODUCT FORMULATION, MANUFACTURE, AND STABILITY STUDIES OF BETHANECHOL CHLORIDE FOR PHASE I CLINIC… | — | $1,644,574 | 0 | — | — |
| 75N91026F00030 | National Institutes Of Health | 126869 B539 & 560 - ROOF REPLACEMENTS | — | $1,511,990 | 0 | — | — |
| 75N91026F00008 | National Institutes Of Health | FY26 126212 - CAMPUS COMPRESSED GAS SECURITY | — | $1,446,242 | 0 | — | — |
| 75N91026F00024 | National Institutes Of Health | IMPLEMENTATION AND CHARACTERIZATION OF IPSC-DERIVED CELL AND ORGANOID MODELS FOR INTEGRATION INTO NEW APPROAC… | — | $1,323,885 | 0 | — | — |
| 75N91026F00021 | National Institutes Of Health | 126889 B571 REPLACE CHILLER #3 | — | $1,291,828 | 0 | — | — |
| 75N91026F00017 | National Institutes Of Health | 126729 ROOM 524 D, E, F | — | $1,102,374 | 0 | — | — |
| 75N91026F00027 | National Institutes Of Health | INTEGRATED DMPK AND TOXICOLOGY PROFILING OF NCATS/TDB MEDICINAL CHEMISTRY LEAD CANDIDATES | — | $1,088,780 | 0 | — | — |
| 75N91026F00011 | National Institutes Of Health | FY26 125346 - B539 STORM DRAIN REPLACEMENT | — | $1,064,983 | 0 | — | — |
| 75N91026F00005 | National Institutes Of Health | FY26 126776 - B567 REPLACE TUNNEL WASHER | — | $901,222 | 0 | — | — |
| 75N91026F00025 | National Institutes Of Health | 126864 MULTI BUILDING DRY CHEM FIRE SUPPRESSION SYSTEM | — | $880,989 | 0 | — | — |
| 75N91026F00004 | National Institutes Of Health | FY26 126746 - B560 EMERGENCY GENERATOR | — | $868,976 | 0 | — | — |
| 75N91026F00031 | National Institutes Of Health | 126297 CAMPUS EVALUATE & REPLACE DEFICIENT ALTERNATING TREAD AND SHIP STAIRS | — | $806,968 | 0 | — | — |
| 75N91026F00018 | National Institutes Of Health | 126827 BUILDING 1023 ROOMS 8 AND 9 BSC REPLACEMENT | — | $652,353 | 0 | — | — |
| 75N91026F00010 | National Institutes Of Health | FY26 TO 10 - B539 CHILLED WATER PUMPS BACKUP POWER | — | $601,085 | 0 | — | — |
| 75N91026F00022 | National Institutes Of Health | FFRDC PTH-1A DRUG PRODUCT FOR PEDIATRIC DOSING | — | $559,073 | 0 | — | — |
| 75N91026F00007 | National Institutes Of Health | 126826 - B1040 UPGRADE CHILLER #2 | — | $478,339 | 0 | — | — |